Close

Baxter BioPharma Solutions (BAX) and Moderna (MRNA) Announce Agreement for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. LRCX
4. IBM
5. HCP
6. SPY
7. BSX
8. PI
9. NOW
10. ORCL


Go back to Baxter BioPharma Solutions (BAX) and Moderna (MRNA) Announce Agreement for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.

Baxter BioPharma Solutions and Moderna Announce Agreement for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.

March 8, 2021 9:00 AM EST

Agreement to perform fill/finish services for approximately 6090 million doses in the U.S. this year Manufacturing will take place at Baxter BioPharma Solutions Indiana facility

DEERFIELD, Ill., AND CAMBRIDGE, Mass..--(BUSINESS WIRE)-- Baxter International Inc. (NYSE: BAX), a global leader in sterile medication production and delivery, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that they have entered into an agreement for Baxter BioPharma Solutions to provide fill/finish... More